Second-line Pembrolizumab for Metastatic Urothelial Carcinoma: Differences in Treatment Outcomes According to the Primary Site.
Nishiyama N, Kita Y, Ito K, Kato M, Hatakeyama S, Matsushita Y, Naito S, Miyake M, Nakanishi S, Kato Y, Shibuya T, Hayashi T, Yasumoto H, Yoshida T, Uemura M, Taoka R, Nishiyama H, Kobayashi T, Kitamura H; Japan Urological Oncology Group.
Nishiyama N, et al. Among authors: nakanishi s.
Anticancer Res. 2023 Nov;43(11):5041-5050. doi: 10.21873/anticanres.16703.
Anticancer Res. 2023.
PMID: 37909969